stain cells before SEM study, thus making identification easier.
Cell samples were prepared (1) by scraping from the cervix, staining and processing for SEM study and (2) by removing cells from colposcopically directed areas on the cervix with a membrane filter. A total of 138 patients were studied and characteristic differences were noted between the surface ultrastructure of benign and malignant cells. Dyskariotic cells showed a mixture of surface types between normal and frankly abnormal. Differences were observed in the SEM between cells that appeared identical by light microscopy. In particular, a tendency to surface abnormality existed on cells that were normal by light microscopy when the cells were adjacent to abnormal cells. A method of assay of CEA not requiring prior extraction has been described. Various essential criteria for a valid radioimmunoassay have been fulfilled; the use of a preparation of labelled CEA reasonably freed of contaminants and of molecules damaged by the labelling reaction, acquisition of specific antibodies, use of an efficient system of separation of free labelled CEA from that bound to antibody (the double antibody technique) and application of the assay method to biological fluids, in particular, serum. The sensitivity of this method allows the detection of 0 5-1 ng/ml of serum; the precision and the reproducibility of the results are very satisfactory.
MEASUREMENT
CEA could be detected in the serum of only 4.2% of 1017 normal subjects. In another group of 7 patients without evidence of urinary infection CEA was determined before and after therapy. In 5 patients in whom treatment was successful CEA excretion declined, contrary to the remainder of this group, who showed both progression of the disease and increase of CEA.
It is concluded that CEA estimations are highly valuable for diagnostic and follow-up purposes in patients with bladder carcinoma provided that urinary infections are absent.
RADIOIMMUNOASSAY OF HCG, of AND f SUBUNITS IN CANCER. P. FRANCHIMONT and A. REUTER. Institute of Medicine, University of Liege, Belgium.
The specific measurement of ,B HCG and native HCG is possible. We have prepared a specific antiserum anti-HCG which does not give any cross-reaction either with the other glycoprotein hormones (follicle stimulating hormone, FSH, luteinizing hormone, LH, thyrostimulating hormone, TSH) or with cx and ,8 subunits of HCG.
Another method for assaying native HCG is to use a system constituted of labelled f subunit with an anti-: subunit antiserum and pure HCG as standard preparation. For the specific measurement of P HCG subunit, we use a homologous system in which the glycoprotein hormones as well as of and P LH subunits do not interfere. For the measurement of the of subunit we have a less specific system. However, correction is possible knowing the normal interference in the sera of normal healthy subjects and not pregnant subjects.
Using Aiming towards a thorough evaluation of the prognosis and the immunological approach of the therapy of cancer patients, nonspecific as well as specific immune reactions have been investigated by in vivo and in vitro tests.
The anamnestic response to PPD (purified protein derivative) tuberculin was investigated by Mantoux tests and leucocyte migration tests. The results show that for 19/38 patients with a positive Mantoux test the average migration inhibition index was 12-43%. The 19 negative patients had an average index of 1-23%. A primary response was investigated by cutaneous sensitization to DNCB (dinitrochlorobenzene).
The specific immune reactions were tested by 51Cr-release lymphocytotoxicity assay against allogeneic tumour cells of the same histological type. The lymphocytotoxicity indices were above 30% for 6/10 melanoma patients and 1/6 breast tumour patients. No healthy individual nor patient with unrelated tumour had an index above 28%. Some correlation between these results and the clinical status of the patients has been observed, however, larger series will be needed for demonstrative evidence.
